

# TRIM15 Antibody (Center) Blocking peptide

Synthetic peptide Catalog # BP13640c

## **Specification**

### TRIM15 Antibody (Center) Blocking peptide - Product Information

Primary Accession

**Q9C019** 

## TRIM15 Antibody (Center) Blocking peptide - Additional Information

**Gene ID 89870** 

#### **Other Names**

Tripartite motif-containing protein 15, RING finger protein 93, Zinc finger protein 178, Zinc finger protein B7, TRIM15, RNF93, ZNF178, ZNFB7

### Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13640c was selected from the Center region of TRIM15. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## TRIM15 Antibody (Center) Blocking peptide - Protein Information

Name TRIM15

Synonyms RNF93, ZNF178, ZNFB7

#### **Function**

E3 ubiquitin ligase that plays a role in several processes including innate antiviral immnity, cell migration and chemotaxis (PubMed:<a href="http://www.uniprot.org/citations/34142270" target="\_blank">34142270</a>, PubMed:<a href="http://www.uniprot.org/citations/23077300" target="\_blank">23077300</a>). Acts as a 'Lys-63'-specific ubiquitin ligase for MAPK1/ERK2 and MAPK3/ERK1, promoting their activation by facilitating their interaction with MAP2K1 and MAP2K2 (PubMed:<a href="http://www.uniprot.org/citations/34497368" target="\_blank">34497368</a>). Plays also a role in cell migration and chemotaxis by acting as a stable focal adhesion component upon recruitment by multi-adapter protein paxillin/PXN (PubMed:<a

href="http://www.uniprot.org/citations/25015296" target="\_blank">25015296</a>). Functions in the RIGI-mediated interferon induction pathway upstream or at the level of MAVS (PubMed:<a



Tel: 858.875.1900 Fax: 858.875.1999

href="http://www.uniprot.org/citations/23077300" target="\_blank">23077300</a>). Inhibits NF-kappa-B activation by turnover of 'Lys-63'-linked ubiquitination of MAP3K7/TAK1. Mechanistically, prevents TRIM8 cytoplasmic translocation and thus inhibits TRIM8- mediated 'Lys-63'-linked polyubiquitination of MAP3K7/TAK1 in the cytoplasm (PubMed:<a href="http://www.uniprot.org/citations/34871740" target="\_blank">34871740</a>). Plays also an important regulatory effect on the activation of hepatic stellate cells (HSCs).

#### **Cellular Location**

Cytoplasm. Nucleus Cell junction, focal adhesion Note=Localizes to focal adhesions during the early stage of adhesion biogenesis.

## TRIM15 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### • Blocking Peptides

TRIM15 Antibody (Center) Blocking peptide - Images

#### TRIM15 Antibody (Center) Blocking peptide - Background

The protein encoded by this gene is a member of thetripartite motif (TRIM) family. The TRIM motif includes threezinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The protein localizes to the cytoplasm. Alternatively spliced transcript variants have been described, buttheir biological validity has not been determined. [provided byRefSeq].

### TRIM15 Antibody (Center) Blocking peptide - References

McElroy, J.P., et al. Hum. Mol. Genet. 19(15):3080-3088(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Barcellos, L.F., et al. PLoS Genet. 5 (10), E1000696 (2009) :Uchil, P.D., et al. PLoS Pathog. 4 (2), E16 (2008) :Lamesch, P., et al. Genomics 89(3):307-315(2007)